LIF was shown to promote migration and metastasis in breast cancer through the AKT-mTOR pathway [54], and elevation of VEGF-A in breast cancer is typically associated with poor prognosis and higher rates of metastasis [75,76]. This evidence concerns the gene AKT1 and breast carcinoma.